journal article·2025-02-14

Visible Light-Triggered Single-Component Photocage Nanoparticles for Combinatorial Photodynamic Therapy and Chemotherapy

Souvik Ray, Pritam Kumar Roy, N. D. Pradeep Singh

ACS Applied Nano Materials· Volume 8· Issue 6
Publisher page

Abstract

Light-triggered chemo-PDT combinatorial therapy is an appealing strategy to advance therapeutic effectiveness and reduce cellular resistance. Herein, we are reporting visible light-activated single-component fluorescent organic nanoparticles (Acr-Cbl nano) based on a π-extended acridine photocage for the combinatorial treatment of chemotherapy and PDT. The high ROS ( 1 O 2 ) generation ability of Acr-Cbl nano, along with the delivery of the anticancer drug chlorambucil, exhibits a combinatorial effect in killing the cancer cells (LN18 glioblastoma) under visible light irradiation. In vitro studies demonstrate that Acr-Cbl nanocrystals can internalize inside the LN18 cells and show enhanced photocytotoxicity, leading to apoptotic cell death.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry

Indian Institute of Technology Kharagpur

School of Medical Science and Technology

Funding

Science and Engineering Research Board

References (31)

Show source-provided references
1. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
2. 10.1038/s41568-024-00679-610.1038/s41568-024-00679-6 ↗
3. 10.3390/cancers1612220510.3390/cancers16122205 ↗
4. 10.3390/cancers302259710.3390/cancers3022597 ↗
5. 10.1158/1535-7163.537.3.510.1158/1535-7163.537.3.5 ↗
6. 10.1002/cjoc.20220033410.1002/cjoc.202200334 ↗
7. 10.1038/nrc107110.1038/nrc1071 ↗
8. 10.1002/adfm.20150272810.1002/adfm.201502728 ↗
9. 10.1039/C5SC00826C10.1039/C5SC00826C ↗
10. 10.1016/j.jconrel.2018.02.00110.1016/j.jconrel.2018.02.001 ↗
11. 10.1021/acsami.8b0826910.1021/acsami.8b08269 ↗
12. 10.1039/C8SC02305K10.1039/C8SC02305K ↗
13. 10.1002/adma.20170483310.1002/adma.201704833 ↗
14. 10.1021/acs.biomac.8b0060710.1021/acs.biomac.8b00607 ↗
15. 10.1021/acsanm.8b0057210.1021/acsanm.8b00572 ↗
16. 10.1021/acsami.5b1119710.1021/acsami.5b11197 ↗
17. 10.1002/adma.20160386410.1002/adma.201603864 ↗
18. 10.1039/D0CC07183H10.1039/D0CC07183H ↗
19. 10.1021/acs.chemrev.0c0066310.1021/acs.chemrev.0c00663 ↗
20. 10.1039/C4MD00481G10.1039/C4MD00481G ↗
21. 10.1021/acsanm.8b0153310.1021/acsanm.8b01533 ↗
22. 10.1016/0165-1110(91)90006-H10.1016/0165-1110(91)90006-H ↗
23. 10.1007/s00280-014-2469-x10.1007/s00280-014-2469-x ↗
24. 10.3390/molecules2801019310.3390/molecules28010193 ↗
25. 10.1039/D3RA01364B10.1039/D3RA01364B ↗
26. 10.1021/acsanm.2c0151510.1021/acsanm.2c01515 ↗
27. 10.1021/j100550a01010.1021/j100550a010 ↗
28. 10.1021/acs.jchemed.5b0048310.1021/acs.jchemed.5b00483 ↗
29. 10.1021/j150619a01510.1021/j150619a015 ↗
30. 10.1039/b201081j10.1039/b201081j ↗
31. 10.1039/c3ob42600a10.1039/c3ob42600a ↗